The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Report from Canada’s Drug Agency says Wegovy cuts risk of heart attack, stroke or cardiovascular death by 20 per cent ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

The results are a boost to Novo Nordisk after another weight-loss therapy ... for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

Astronomers have observed a galaxy dating to an earlier epoch in the universe's history that surprisingly is shaped much like ...

Ireland has pivoted to oppose contentious European Union reforms aimed at broadening access to new drugs and medicines, ...